The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide
Open accessAbstract
PURPOSE: The therapeutic index (TI) is the range of doses at which a medication is effective without unacceptable adverse events. Drugs with a narrow TI (NTIDs) have a narrow window between their effective doses and those at which they produce adverse toxic effects. Generic drugs may be substituted for brand-name drugs provided that they meet the recommended bioequivalence (BE) limits. However, an appropriate range of BE for NTIDs is essential to define due to the potential for ineffectiveness or adverse events. Flecainide is an antiarrhythmic agent that has the potential to be considered an NTID. This review aims to evaluate the literature surrounding guidelines on generic substitution for NTIDs and to evaluate the evidence for flecainide to be considered an NTID. METHODS: A review of recommendations from various regulatory authorities regarding BE and NTIDs, and publications regarding the NTID characteristics of flecainide, was carried out. RESULTS: Regulatory authorities generally recommend reduced BE limits for NTIDs. Some, but not all, regulatory authorities specify flecainide as an NTID. The literature review demonstrated that flecainide displays NTID characteristics including a steep drug dose-response relationship for safety and efficacy, a need for therapeutic drug monitoring of pharmacokinetic (PK) or pharmacodynamics measures and intra-subject variability in its PK properties. CONCLUSIONS: There is much evidence for flecainide to be considered an NTID based on both preclinical and clinical data. A clear understanding of the potential of proarrhythmic effects or lack of efficacy, careful patient selection and regular monitoring are essential for the safe and rational administration of flecainide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,115
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,822
Self-citationEcht, D. S., Liebson, P. R., Mitchell, L. B., Peters, R. W., Obias-Manno, D., Barker, A. H., Arensberg, D., Baker, A., Friedman, L., Greene, H. L., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241201 · Cited by 3,253
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs253 · Cited by 2,899
Self-citationFuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177292 · Cited by 2,805
Self-citationSchuirmann, D. J. (1987) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01068419 · Cited by 2,696
Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., Gregoratos, G., Klein, G., Myerburg, R. J., Quinones, M. A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.010 · Cited by 1,973
Self-citationBasic and Clinical Pharmacology
Katzung, B. G. (1982) · Andalas University Repository (Andalas University) · Cited by 1,914
Drug Metabolism and Variability among Patients in Drug Response
Wilkinson, G. R. (2005) · New England Journal of Medicine · doi:10.1056/nejmra032424 · Cited by 1,185
(2017) · Arzneimittelforschung · doi:10.1055/s-00000175 · Cited by 1,134
Basic and clinical pharmacology
Traynor, J. R. (1988) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/0731-7085(88)80021-9 · Cited by 1,126
2012 Focused Update of the ESC Guidelines for the Management of Atrial Fibrillation
Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., & Kirchhof, P. (2013) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2012.11.003 · Cited by 687
The Cardiac Arrhythmia Suppression Trial: Casting Suppression in a Different Light
Pratt, C. M., & Moyé, L. A. (1995) · Circulation · doi:10.1161/01.cir.91.1.245 · Cited by 460
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation
Lafuente-Lafuente, C., Valembois, L., Bergmann, J.-F., & Belmin, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005049.pub4 · Cited by 423
Bertilsson, L., Lou, Y.-Q., Du, Y.-L., Liu, Y., Kuang, T.-Y., Liao, X.-M., Wang, K.-Y., Reviriego, J., Iselius, L., & Sjöqvist, F. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.38 · Cited by 399
Davit, B. M., Nwakama, P. E., Buehler, G. J., Conner, D. P., Haidar, S. H., Patel, D. T., Yang, Y., Yu, L. X., & Woodcock, J. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m141 · Cited by 330
Anderson, J. L., Halperin, J. L., Albert, N. M., Bozkurt, B., Brindis, R. G., Curtis, L. H., DeMets, D., Guyton, R. A., Hochman, J. S., Kovacs, R. J., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.001 · Cited by 311
Anderson, J. L., Gilbert, E. M., Alpert, B. L., Henthorn, R. W., Waldo, A. L., Bhandari, A. K., Hawkinson, R. W., & Pritchett, E. L. (1989) · Circulation · doi:10.1161/01.cir.80.6.1557 · Cited by 287
Flecainide: Its proarrhythmic effect and expected changes on the surface electrocardiogram
Morganroth, J., & Horowitz, L. N. (1984) · The American Journal of Cardiology · doi:10.1016/0002-9149(84)90509-5 · Cited by 280
Crijns, H. J., Van Gelder, I. C., Van Gilst, W. H., Hillege, H., Gosselink, A. M., & Lie, K. I. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90828-9 · Cited by 275
Astemizole: A Review of its Pharmacodynamic Properties and Therapeutic Efficacy
Richards, D. M., Brogden, R. N., Heel, R. C., Speight, T. M., & Avery, G. S. (1984) · Drugs · doi:10.2165/00003495-198428010-00003 · Cited by 259
Freemantle, N., Lafuente-Lafuente, C., Mitchell, S., Eckert, L., & Reynolds, M. (2011) · Europace · doi:10.1093/europace/euq450 · Cited by 245
Oral Flecainide Acetate for the Treatment of Ventricular Arrhythmias
Anderson, J. L., Stewart, J. R., Perry, B. A., Van Hamersveld, D. D., Johnson, T. A., Conard, G. J., Chang, S. F., Kvam, D. C., & Pitt, B. (1981) · New England Journal of Medicine · doi:10.1056/nejm198108273050901 · Cited by 222
Bioequivalence and other unresolved issues in generic drug substitution
Meredith, P. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80340-5 · Cited by 213
McNamara, R. L., Tamariz, L. J., Segal, J. B., & Bass, E. B. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-12-200312160-00012 · Cited by 211
Conard, G. J., & Ober, R. E. (1984) · The American Journal of Cardiology · doi:10.1016/0002-9149(84)90501-0 · Cited by 203
Van Gelder, I. C., Crijns, H. J. G. M., Van Gilst, W. H., Van Wijk, L. M., Hamer, H. P. M., & Lie, K. I. (1989) · The American Journal of Cardiology · doi:10.1016/0002-9149(89)90574-2 · Cited by 187
Proarrhythmia in Patients Treated for Atrial Fibrillation or Flutter
Falk, R. H. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-2-141 · Cited by 185
Beta-blocker therapy in the cardiac arrhythmia suppression trial
Kennedy, H. L., Brooks, M. M., Barker, A. H., Bergstrand, R., Huther, M. L., Beanlands, D. S., Bigger, J. T., Goldstein, S., & The CAST Investigators (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90308-5 · Cited by 171
Aliot, E., Capucci, A., Crijns, H. J., Goette, A., & Tamargo, J. (2011) · Europace · doi:10.1093/europace/euq382 · Cited by 167
Self-citationHarmer, A., Valentin, J.-P., & Pollard, C. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01415.x · Cited by 158
Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide
Duff, H. J., Roden, D. M., Maffucci, R. J., Vesper, B. S., Conard, G. J., Higgins, S. B., Oates, J. A., Smith, R. F., & Woosley, R. L. (1981) · The American Journal of Cardiology · doi:10.1016/0002-9149(81)90331-3 · Cited by 149
Hellestrand, K. J., Bexton, R. S., Nathan, A. W., Spurrell, R. A., & Camm, A. J. (1982) · Heart · doi:10.1136/hrt.48.2.140 · Cited by 142
Naccarelli, G. V., Dorian, P., Hohnloser, S. H., & Coumel, P. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89118-7 · Cited by 134
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation
Lafuente‐Lafuente, C., Mouly, S. J., Longás-Tejero, M. A., & Bergmann, J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005049.pub2 · Cited by 118
Pharmacological Cardioversion of Atrial Fibrillation: Current Management and Treatment Options
Boriani, G., Diemberger, I., Biffi, M., Martignani, C., & Branzi, A. (2004) · Drugs · doi:10.2165/00003495-200464240-00003 · Cited by 110
Allot, E., & Denjoy, I. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89120-5 · Cited by 98
Novel bioequivalence approach for narrow therapeutic index drugs
Yu, L., Jiang, W., Zhang, X., Lionberger, R. A., Makhlouf, F., Schuirmann, D. J., Muldowney, L., Chen, M.-L., Davit, B. M., Conner, D. P., et al. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.28 · Cited by 97
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation
Lafuente‐Lafuente, C., Longás-Tejero, M. A., Bergmann, J., & Belmin, J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005049.pub3 · Cited by 96
Coromilas, J., Saltman, A. E., Waldecker, B., et al. (1995) · Circulation · doi:10.1161/01.cir.91.8.2245 · Cited by 89
Determinants of the interindividual variability in response to antiplatelet drugs
Rocca, B., & Patrono, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01380.x · Cited by 89
Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter
Pietersen, A. H., & Hellemann, H. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90527-r · Cited by 88
Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs
Nattel, S. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00293-9 · Cited by 81
Electrophysiologic properties of flecainide acetate
Estes, N. A. M., Garan, H., & Ruskin, J. N. (1984) · The American Journal of Cardiology · doi:10.1016/0002-9149(84)90498-3 · Cited by 79
Anderson, J. L., Lutz, J. R., & Allison, S. (1983) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(83)80382-9 · Cited by 78
Funck‐Brentano, C., Becquemont, L., Kroemer, H. K., Bühl, K., Knebel, N. G., Eichelbaum, M. F., & Jaillon, P. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.26 · Cited by 77
Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias
Hohnloser, S. H., & Zabel, M. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)91071-b · Cited by 74
Friedman, P. L., & Stevenson, W. G. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00586-4 · Cited by 71
Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias
Pritchett, E. L. C., & Wilkinson, W. E. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90170-p · Cited by 67
CHIMIENTI, M., CULLEN, M. T., & Casadei, G. (1995) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a060852 · Cited by 64
Flecainide Versus Quinidine in the Prevention of Paroxysms of Atrial Fibrillation
van Wijk, L. M., den Heijer, P., Crijns, H. J. G. M., van Gilst, W. H., & Lie, K. I. (1989) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-198901000-00005 · Cited by 54
Innovative Approaches for Demonstration of Bioequivalence: the US FDA Perspective
Zhang, X., Zheng, N., Lionberger, R. A., & Yu, L. X. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.41 · Cited by 48
Tamargo, J. L., Capucci, A., & Mabo, P. (2012) · Drug Safety · doi:10.2165/11599950-000000000-00000 · Cited by 46
Self-citationFlecainide acetate in atrial flutter and fibrillation
Sihm, I., HANSEN, F. A., RASMUSSEN, J., Pedersen, A. K., & Thygesen, K. A. (1990) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a059670 · Cited by 44
Verbeeck, R. K., & Musuamba, F. T. (2012) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3vc8j · Cited by 43
Generic drugs - safe, effective, and affordable
Peters, J. R., Hixon, D., Conner, D. P., Davit, B. M., Catterson, D. M., & Parise, C. M. (2009) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2009.01236.x · Cited by 39
Doki, K., Homma, M., Kuga, K., Aonuma, K., & Kohda, Y. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03435.x · Cited by 37
Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study
Andersen, S. S., Hansen, M. L., Gislason, G., Schramm, T. K., Folke, F., Fosbøl, E. L., Abildstrom, S. Z., Madsen, M., Køber, L., & Torp-Pedersen, C. T. (2009) · EP Europace · doi:10.1093/europace/eup119 · Cited by 37
Almroth, H., Andersson, T., Fengsrud, E., Friberg, L., Linde, P., Rosenqvist, M., & Englund, A. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02395.x · Cited by 37
Doki, K., Homma, M., Kuga, K., Kusano, K., Watanabe, S., Yamaguchi, I., & Kohda, Y. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0188-x · Cited by 36
Gulizia, M. M., Mangiameli, S., Orazi, S., Chiarandà, G., Piccione, G., Giovanni, N. D., Colletti, A., Pensabene, O., Lisi, F., Vasquez, L., et al. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.08.033 · Cited by 34
ACCF/AHA 2011 Health Policy Statement on Therapeutic Interchange and Substitution
Holmes, D. R., Becker, J. A., Granger, C. B., Limacher, M. C., Page, R. L., II, Sila, C. A., Drozda, J. P., Cacchione, J. G., Erb, B. D., Harrington, R. A., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.001 · Cited by 34
Holmes, D. R., Becker, J. A., Granger, C. B., Limacher, M. C., Page, R. L., II, & Sila, C. A. (2011) · Circulation · doi:10.1161/cir.0b013e31822d97d5 · Cited by 32
Flecainide dose-response relations in stable ventricular arrhythmias
Woosley, R. L., Siddoway, L. A., Duff, H. J., et al. (1984) · The American Journal of Cardiology · doi:10.1016/0002-9149(84)90504-6 · Cited by 31
Genetic and environmental factors causing variation in drug response
Vesell, E. S. (1991) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(91)90020-o · Cited by 29
Naccarelli, G. V., Wolbrette, D. L., & Luck, J. C. (2001) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70324-2 · Cited by 28
Taylor, R., Gandhi, M. M., & Lloyd, G. (2010) · BMJ · doi:10.1136/bmj.b4684 · Cited by 26
Paranoid Psychosis and Myoclonus: Flecainide Toxicity in Renal Failure
Ting, S. M. S., Lee, D., Maclean, D., & Sheerin, N. (2008) · Cardiology · doi:10.1159/000119694 · Cited by 26
Life-Threatening Flecainide Intoxication in a Young Child Secondary to Medication Error
D’Alessandro, L. C. A., Rieder, M. J., Gloor, J., Freeman, D., & Buffo-Sequiera, I. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l549 · Cited by 26
A proposal for the clinical use of flecainide
Anderson, J. L., Stewart, J. R., & Crevey, B. J. (1984) · The American Journal of Cardiology · doi:10.1016/0002-9149(84)90514-9 · Cited by 25
Flecainide Pharmacokinetics After Multiple Dosing in Patients with Impaired Renal Function
Forland, S. C., Cutler, R. E., McQuinn, R. L., Kvam, D. C., Miller, A. M., Conard, G. J., & Parish, S. (1988) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1988.tb03207.x · Cited by 22
Endrényi, L., & Tóthfalusi, L. (2013) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j31k51 · Cited by 20
Steinbeck, G., Doliwa, R., & Bach, P. (2008) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-2008-1067903 · Cited by 18
CYP2D6 genotype affects age-related decline in flecainide clearance
Doki, K., Homma, M., Kuga, K., Aonuma, K., & Kohda, Y. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283588fe5 · Cited by 18
Assessment of serum flecainide trough levels in patients with tachyarrhythmia
Homma, M., Kuga, K., Doki, K., Katori, K., Yamaguchi, I., Sugibayashi, K., & Kohda, Y. (2004) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357055128 · Cited by 18
Carunchio, A., Fera, M. S., Mazza, A., Burattini, M., Greco, G., Galati, A., & Ceci, V. (1995) · PubMed · Cited by 17
Aliot, E., Roy, L. D., Capucci, A., Hernández, J. R. L., Denjoy, I., Lupoglazoff, J., & Coumel, P. (2003) · Annales de Cardiologie et d Angéiologie · doi:10.1016/s0003-3928(02)00183-x · Cited by 12
Cited by
Hypothyroidism in Context: Where We’ve Been and Where We’re Going
Chiovato, L., Magri, F., & Carlé, A. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01080-8 · Cited by 459
Amorim, A. M. B., Piochi, L. F., Gaspar, A. T., Preto, A. J., Rosário-Ferreira, N., & Moreira, I. S. (2024) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.3c00352 · Cited by 132
A practical guide for the generation of model-based virtual clinical trials
Craig, M., Gevertz, J. L., Kareva, I., & Wilkie, K. P. (2023) · Frontiers in Systems Biology · doi:10.3389/fsysb.2023.1174647 · Cited by 52
Control of fibrosis with enhanced safety via asymmetric inhibition of prolyl‐tRNA synthetase 1
Yoon, I., Kim, S., Cho, M., You, K. A., Son, J., Lee, C., Suh, J. H., Bae, D., Kim, J. M., Oh, S., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202216940 · Cited by 22
Unveiling Drug-Drug Interactions in Dental Patients: A Retrospective Real-World Study
Colibășanu, D., Ardelean, S. M., Goldiș, F.-D., Drăgoi, M.-M., Vasii, S.-O., Maksimović, T., Colibășanu, Ș., Șoica, C., & Udrescu, L. (2025) · Dentistry Journal · doi:10.3390/dj13060255 · Cited by 9
Metadata
- Authors
- Tamargo, J., Le Heuzey, J.-Y., & Mabo, P.
- Venue
- European Journal of Clinical Pharmacology
- Published
- 2015-04-15
- Volume
- 71
- Issue
- 5
- Pages
- 549-567
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2109622977
- Cited by
- 276
- References
- 77
- FWCI
- 27.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.